Sec Form 3 Filing - Huh Yong-Jun @ Artiva Biotherapeutics, Inc. - 2024-07-18

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Huh Yong-Jun 2. Issuer Name and Ticker or Trading Symbol Artiva Biotherapeutics, Inc. [ ARTV] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O ARTIVA BIOTHERAPEUTICS, INC., 5505 MOREHOUSE DRIVE, SUITE 100 3. Date of Earliest Transaction (MM/DD/YY) 07/18/2024 (Street) SAN DIEGO, CA92121 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 348,837 I By GC Corp ( 1 ) Common Stock 232,558 I By GC Cell Corporation ( 2 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series A Preferred Stock ( 3 ) ( 3 ) ( 3 ) Common Stock 667,185 I By GC Corp ( 1 ) Series B Preferred Stock ( 3 ) ( 3 ) ( 3 ) Common Stock 330,095 I By GC Corp ( 1 ) Series A Preferred STock ( 3 ) ( 3 ) ( 3 ) Common Stock 292,791 I By GC Cell Corporation ( 2 ) Series B Preferred Stock ( 3 ) ( 3 ) ( 3 ) Common Stock 62,181 I By GC Cell Corporation ( 2 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Huh Yong-Jun C/O ARTIVA BIOTHERAPEUTICS, INC. 5505 MOREHOUSE DRIVE, SUITE 100 SAN DIEGO, CA92121 X Signatures /s/ Jennifer Bush, Attorney-in-Fact 07/18/2024 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The shares are held directly by GC Corp. Mr. Yong-Jun Huh is Chief Executive Officer of GC Corp. GC Corp., a public Korean holdings company, is ultimately controlled by its board of directors, consisting of Mr. Yong-Jun Huh, Huh II-Sup, Park Yong-Tae and Kim Seok-Hwa. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and each disclaims beneficial ownership of all shares held by such entity, except to the extent of any pecuniary interest therein. ( 2 )The shares are held directly by GC Cell Corporation. Mr. Yong-Jun Huh is Chief Executive Officer of GC Corp. GC Corp., a public Korean holdings company, which is the parent company of GC Cell Corporation and is ultimately controlled by its board of directors, consisting of Mr. Yong-Jun Huh, Huh II-Sup, Park Yong-Tae and Kim Seok-Hwa. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and GC Cell Corporation and each disclaims beneficial ownership of all shares held by such entities, except to the extent of any pecuniary interest therein. ( 3 )Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") is convertible into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering, the Preferred Stock willconvert into the number of shares of Common Stock of the Issuer shown in column 3. The Preferred Stock has no expiration date.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.